VACCINE DELIVERY SYSTEM
Vaccine Delivery System
Akagera Medicines is developing mRNA vaccines against some of the world’s most intractable pathogens together with our partners: CEPI, NIH/VRC, EIB, Gates, and universities. These include Tuberculosis, HIV, and Lassa Fever.
Akagera is also applying it’s high efficiency targeted lipid nanoparticle (LNP) delivery system to established targets like influenza and RSV to improve affordability and accessibility by LMICs. Finally, we are being responsive to emerging viruses as part of our pandemic preparedness with vaccines against Avian (H5N1) Flu.
Mark Hayes | Vice President, Research
“The world demands vaccines that provide durable protection measured in many years and works on all variants of the disease. Furthermore, it must be cost-effective, equitably distributed, and eventually manufactured by those who need it most. We have been working on these solutions since day one.”
Our Science
(akagera medicines has achieved preclinical proof of concept)
technology
Liposomal particles, which consist of ionizable lipids, phospholipids, and cholesterol – encapsulate mRNA molecules that target and bind to the dendritic cells, the gateway to the immune system.
mechanism of action
Additional Resources & News